Survival from breast cancer in women with a BRCA2 mutation by treatment.
Survival from breast cancer in women with a BRCA2 mutation by treatment.
复制标题
DOI：
10.1038/s41416-020-01164-1
复制
发表时间：
2021-04
影响因子：
8.8
通讯作者：
kConFab Investigators, Polish Hereditary Breast Cancer Consortium, Hereditary Breast Cancer Clinical Study Group
中科院分区：
文献类型：
--
作者：
Evans DG;Phillips KA;Milne RL;Fruscio R;Cybulski C;Gronwald J;Lubinski J;Huzarski T;Hyder Z;Forde C;Metcalfe K;Senter L;Weitzel J;Tung N;Zakalik D;Ekholm M;Sun P;Narod SA;kConFab Investigators, Polish Hereditary Breast Cancer Consortium, Hereditary Breast Cancer Clinical Study Group
尚未研究各种乳腺癌治疗对 BRCA2 突变患者的影响。我们试图评估双侧卵巢切除术和其他治疗对具有种系 BRCA2 突变的乳腺癌特异性生存的影响。我们通过结合五个不同的数据集（回顾性和前瞻性），确定了 664 名患有 I-III 期乳腺癌和 BRCA2 突变的女性。受试者从诊断出乳腺癌到死亡，随访时间为 7.2 年。肿瘤特征和癌症治疗由患者报告并源自医疗记录。使用 Cox 比例风险模型确定生存预测因子，并根据其他治疗和预后特征进行调整。 ER 阳性患者的 10 年乳腺癌生存率为 78.9%，ER 阴性患者的 10 年乳腺癌生存率为 82.3%（调整后 HR = 1.23（95% CI，0.62–2.45，p = 0.55））。接受双侧卵巢切除术的女性的 10 年乳腺癌生存率为 89.1%，未接受卵巢切除术的女性的 10 年乳腺癌生存率为 59.0%（调整后 HR = 0.45；95% CI，0.28–0.72，p = 0.001）。化疗的调整后风险比为 0.83 (95% CI, 0.65–1.53: p = 0.56)。对于患有乳腺癌且存在种系 BRCA2 突变的女性，ER 状态呈阳性并不能预测较高的生存率。卵巢切除术可降低乳腺癌死亡风险，应在治疗计划中予以考虑。
The impact of various breast-cancer treatments on patients with a BRCA2 mutation has not been studied. We sought to estimate the impact of bilateral oophorectomy and other treatments on breast cancer-specific survival among patients with a germline BRCA2 mutation. We identified 664 women with stage I–III breast cancer and a BRCA2 mutation by combining five different datasets (retrospective and prospective). Subjects were followed for 7.2 years from diagnosis to death from breast cancer. Tumour characteristics and cancer treatments were patient-reported and derived from medical records. Predictors of survival were determined using Cox proportional hazard models, adjusted for other treatments and for prognostic features. The 10-year breast-cancer survival for ER-positive patients was 78.9% and for ER-negative patients was 82.3% (adjusted HR = 1.23 (95% CI, 0.62–2.45, p = 0.55)). The 10-year breast-cancer survival for women who had a bilateral oophorectomy was 89.1% and for women who did not have an oophorectomy was 59.0% (adjusted HR = 0.45; 95% CI, 0.28–0.72, p = 0.001). The adjusted hazard ratio for chemotherapy was 0.83 (95% CI, 0.65–1.53: p = 0.56). For women with breast cancer and a germline BRCA2 mutation, positive ER status does not predict superior survival. Oophorectomy is associated with a reduced risk of death from breast cancer and should be considered in the treatment plan.
登录
查看更多内容
为绝经前乳腺癌调整辅助内分泌疗法。
DOI：
10.1056/nejmoa1803164
发表时间：
2018-07-12
期刊：
The New England journal of medicine
影响因子：
--
作者：
Francis PA;Pagani O;Fleming GF;Walley BA;Colleoni M;Láng I;Gómez HL;Tondini C;Ciruelos E;Burstein HJ;Bonnefoi HR;Bellet M;Martino S;Geyer CE Jr;Goetz MP;Stearns V;Pinotti G;Puglisi F;Spazzapan S;Climent MA;Pavesi L;Ruhstaller T;Davidson NE;Coleman R;Debled M;Buchholz S;Ingle JN;Winer EP;Maibach R;Rabaglio-Poretti M;Ruepp B;Di Leo A;Coates AS;Gelber RD;Goldhirsch A;Regan MM;SOFT and TEXT Investigators and the International Breast Cancer Study Group
通讯作者：
SOFT and TEXT Investigators and the International Breast Cancer Study Group
影响因子：
11.5
作者：
Foulkes, WD;Metcalfe, K;Narod, SA
通讯作者：
Narod, SA
影响因子：
45.3
作者：
Phillips, KA;Milne, RL;Hopper, JL
通讯作者：
Hopper, JL
影响因子：
45.3
作者：
Goodwin, Pamela J.;Phillips, Kelly-Anne;Longacre, Teri A.
通讯作者：
Longacre, Teri A.
影响因子：
8.8
作者：
Olafsdottir EJ;Borg A;Jensen MB;Gerdes AM;Johansson ALV;Barkardottir RB;Johannsson OT;Ejlertsen B;Sønderstrup IMH;Hovig E;Lænkholm AV;Hansen TVO;Olafsdottir GH;Rossing M;Jonasson JG;Sigurdsson S;Loman N;Nilsson MP;Narod SA;Tryggvadottir L
通讯作者：
Tryggvadottir L